華潤醫藥(03320.HK):東阿阿膠預計年度由虧轉盈3346萬至4977萬元
格隆匯1月29日丨華潤醫藥(03320.HK)公吿,公司附屬東阿阿膠(000423.SZ)預計截至2020年12月31日止年度歸屬於東阿阿膠股東的淨利潤約人民幣3,346萬元至人民幣4,977萬元(上年同期:淨虧損約人民幣44,392萬元)、扣除非經常性損益後淨虧損預計約人民幣2,919萬元至人民幣4,549萬元(上年同期:淨虧損約人民幣53,679萬元)、營業收入預計約人民幣335,818萬元至人民幣352,951萬元(上年同期:約人民幣295,862萬元)。
本次業績變動的主要原因為:1.積極作為,工作開展創新高效。東阿阿膠數字化轉型初步成功,堅持以消費者為中心,建立新增長邏輯,把顧客運營能力打造成東阿阿膠繼品牌之後的核心競爭力。東阿阿膠創新活力顯着增強,堅持精細化管理,加快產品開發,突破醫理藥效及技術研究,以金牌的工作品質創金牌的產品品質。東阿阿膠組織效能持續提升,圍繞“小總部、大業務、生態化、敏捷化、平台化”原則,構建前中後台融合的組織結構,有效承接公司戰略。2.展望未來,信心百倍堅定前行。2021年是東阿阿膠數字化轉型的提速之年,東阿阿膠將積極迴應國家促進中醫藥傳承創新發展號召,深化商業模式創新,推進“十四五”戰略實施,實現東阿阿膠高品質發展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.